Gynaecomastia in two men on stable antiretroviral therapy who commenced treatment for tuberculosis by Kratz, Jeremy D. et al.
MMJ VOL 28 (4): December 2016
Malawi Medical Journal 28 (4): December 2016 Gynaecomastia in two men on ART and TB treatment 185
http://dx.doi.org/10.4314/mmj.v28i4.8
Case presentations
1. A 32-year-old man presented to an urban outpatient clinic 
in Beira, Mozambique with bilateral gynaecomastia. The 
patient had been diagnosed with World Health Organization 
(WHO) stage III HIV disease two years prior to presentation 
and was maintained on an antiretroviral therapy (ART) 
regimen containing tenofovir (TDF) 300 mg daily, lamivudine 
(3TC) 300 mg daily, and efavirenz (EFV) 600 mg daily. Eight 
months prior to presentation, he developed cough and 
weight loss, at which time he was diagnosed with pulmonary 
tuberculosis (TB). Therapy included a two-month regimen 
of  rifampin (R) 600 mg daily, isoniazid (H) 300 mg daily, 
pyrazinamide (Z) 1600 mg daily, and ethambutol (E) 1100 
mg daily, followed by four months of  rifampin 600 mg daily 
and isoniazid 300 mg daily (HRZE protocol). Two months 
into therapy he noted progressive nontender bilateral breast 
fullness. He denied alcohol, tobacco, or herbal medication 
use. He reported taking ART medications only as directed, 
without dosage changes. Review of  systems was negative for 
abdominal distention, melaena, headache, vision changes, 
decreased libido, erectile dysfunction, or galactorrhoea. 
On examination, the patient was a well-appearing male, 
afebrile, with normal vital signs. Chest exam was notable 
for bilateral nontender gynaecomastia, shown in Figure 
1A. The remainder of  the physical exam was normal, 
including an abdomen without organomegaly or ascites, 
skin without spider telangiectasia, normal male hair pattern, 
normal phallus, and testes without masses. Two months 
after completing TB therapy, his breasts remained enlarged 
without further progression.
2. A 68-year-old man presented to the same outpatient clinic 
with acute onset of  dysuria and secondary concern for breast 
enlargement. The patient had been diagnosed with WHO 
stage III HIV disease seven years prior to presentation and 
was maintained on ART containing zidovudine (AZT) 300 
mg twice daily, 3TC 150 mg twice daily, and EFV 600 mg 
daily. Two months prior to presentation, he had completed 
a 6-month course of  HRZE therapy (dosing as previously 
noted) for pulmonary TB. His breast fullness developed 
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ten weeks after initiating HRZE therapy and persisted after 
completion. He denied fevers, chills, haematuria, abdominal 
pain, galactorrhoea, change in libido, or erectile dysfunction. 
On exam, he was a well-appearing male, afebrile, with 
normal vital signs. Findings on his chest exam (bilateral 
nontender gynaecomastia) are shown in Figure 1B. Rectal 
examination revealed an enlarged, tender, smooth prostate, 
without focal masses. The remainder of  his exam revealed 
no hepatosplenomegaly, ascites, or spider telangiectasia, 
with normal phallus, testes without masses, and a normal 
male hair pattern. Given his dysuria and tender prostate, he 
was diagnosed and treated for prostatitis with a course of  
trimethoprim-sulfamethoxazole.
Discussion
Gynaecomastia is benign enlargement of  the male breast, 
resulting from hyperplasia of  underlying ductal tissue. The 
course of  physiological gynaecomastia varies from reversible 
changes in puberty to permanent age-related manifestations.1 
Other common aetiologies include endocrine disorders, 
hormone-secreting malignancies, severe hepatic dysfunction, 
and medication side effects. It was previously proposed 
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Abstract
Gynaecomastia is a common clinical presentation that varies from benign presentations in stages of  human development to hormonal pathology, 
mainly due to hepatic dysfunction, malignancy, and adverse pharmacologic effects. We describe the development of  significant bilateral gynaecomastia 
after starting treatment for pulmonary tuberculosis (TB) in two males with WHO stage III Human Immunodeficiency Virus (HIV) infection on stable 
antiretroviral regimens.
Emerging reports suggest that distinct hepatic impairment in efavirenz metabolism modulates oestrogenic activity, which may be potentiated by anti-
tuberculosis therapy. Clinical application includes early recognition of  efavirenz-induced gynaecomastia, especially after commencing tuberculosis 
treatment. To avoid decreased adherence resulting from the distressing side effect of  gynecomastia, transition to an alternative ART regimen over the 
course of  tuberculosis treatment should be considered.
Figure 1: Chest examination two months after completion of 
tuberculosis treatment
A) 34-year-old man in case 1
B) 68-year old-man in case 2
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Medications 
Isonizazid* Reduced B6-mediated 
  metabolism 
NNRTI* Oestrogen receptor
  modulation 
NRTI* Unknown 



















Non-nucleoside reverse transcriptase inhibitors (NNRTI)
efavirenz**
Nucleoside reverse transcriptase inhibitors (NRTI)
lamivudine***, stavudine***, zidovudine***
Protease inhibitors (PI)
indinavir***, lopinavir***, nelfinavir***, ritonavir***, saquinavir***
Cardiovascular
amiodarone*, amlodipine***, atorvastatin*, captopril*, clonidine*, digoxin*, 
diltiazem**, felodipine**, lisinopril*, nifedipine**, pravastatin*, 
rosuvastatin*, spironolactone***, verapamil**
Environmental/Exogenous










actinomycin D**, bicalutamide***, bleomycin**, carmustine**, cisplatin**, 
cyclophosphamide**, cyproterone acetate*, cytarabine**, dasatinib*, 
dutasteride***, etoposide**, finasteride***, flutamide***, imatinib*, 
melphalan**, methotrexate**, nilutamide***, procarbazine**, vincristine**, 
sunitinib*
Psychiatric
haloperidol**, olanzapine**, paliperidone**, risperidone**, ziprasidone**, 





auranofin*, penicillamine*, etretinate*, sulindac*
A
B
A) System-based medication review for gynaecomastia3 
B) Synergistic mechanisms for gynaecomastia in patients with HIV/AIDS and tuberculosis
Figure 2: Gynaecomastia as a result of synergy between medications and infectious disease
Many agents have been implicated in the development of  
gynaecomastia, including ART and antimicrobial agents (see 
Figure 2A).5 HIV and TB are both independent risk factors 
for hypogonadotrophic hypogonadism, with rates reported 
as high as 75%6 and 73%,7 respectively, but these may have 
been influenced by cachexia in an era when effective HIV 
treatment was not available. No evidence of  hypogonadism 
or lipodystrophy was found on the physical examinations of  
these patients. Although refeeding syndrome5 and immune 
reconstitution-induced gynaecomastia has been reported,8 
these were unlikely causes, given the stable ART regimens 
(two and seven years) prior to initiation of  therapy for TB.
Both histories favour potentiation of  an otherwise stable 
ART regimen by the addition of  HRZE. The time course, 
with progression over six months, suggested this potentiation 
by rifampin or isoniazid rather than ethambutol and 
pyrazinamide, which were given only in the first two months of  
HRZE. While there are few isolated isoniazid-induced cases 
that EFV-induced gynaecomastia was mediated by either 
immune reconstitution or direct oestradiol-like effects, with 
mean clinical resolution at five months following removal 
of  EFV.2 A previous case series reported six patients from 
Nigeria who developed gynaecomastia on EFV therapy; 
in five of  these cases, the gynaecomastia resolved upon 
discontinuation of  EFV.3 A report from Malawi described 
two male patients who developed gynaecomastia over their 
course of  ART containing EFV, including one patient who 
received concomitant HRZE therapy for TB.4 This case 
report builds upon these prior findings with the description 
of  two additional cases of  gynaecomastia from Mozambique. 
The two males infected with HIV were on stable ART 
containing EFV. They developed bilateral gynaecomastia 
after commencement of  concurrent treatment for TB. While 
prior reports implicate EFV as the potential cause, this 
work builds on an evolving mechanistic understanding that 
highlights treatment interactions between HRZE and EFV. 
Figure 2: Gynaecomastia as  result of synergy between medications and infectious disease
A) System-based medication review for gynaecomastia3
B) Synergistic mechanisms for gynaecomastia in patients with HIV/AIDS and tuberculosis
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of  gynaecomastia reported,9 EFV may be more significant in 
potential causality, especially with the potentiating interaction 
with rifampin. Large prospective studies have documented 
an association between gynaecomastia and EFV and 
didanosine.10 EFV is known to induce gynaecomastia by 
direct oestrogen receptor modulation,2 an effect that varies 
with ethnicity and weight.11 Mutations in CYP2B6 have 
been reported throughout Africa,12 as well as in Germany,13 
resulting in impaired hepatic metabolism of  EFV. Notably, 
these mutations have paradoxically augmented EFV levels 
with concurrent HRZE therapy.14
We report two patients with stable WHO stage III HIV 
disease, on EFV-containing ART regimens, who developed 
significant gynaecomastia during therapy for pulmonary TB. 
A prior report highlighted resolution of  gynaecomastia in 
about 80% of  patients on EFV-containing ART after change 
in therapy.8 Early recognition of  gynaecomastia may prompt 
an early switch from an EFV-containing ART regimen to 
prevent worsening and effect reversal of  this condition. 
Prior work has highlighted an algorithmic approach to 
managing gynaecomastia, including first identifying benign 
developmental aetiologies, and a recommendation for 
removal of  potential offending agents.15 While gynaecomastia 
may be clinically benign, it can be stigmatising for patients, 
who may compromise their medication adherence because 
of  these concerns.
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